Jasper Therapeutics Inc. (JSPR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -71,269 | -46,948 | -28,311 | -13,728 | -64,465 |
| Depreciation Amortization | 1,373 | 1,128 | 587 | 288 | 1,108 |
| Accounts receivable | N/A | N/A | N/A | N/A | 663 |
| Accounts payable and accrued liabilities | -122 | -1,079 | -1,301 | -1,758 | 2,381 |
| Other Working Capital | 184 | -658 | -2,579 | -3,581 | 5,103 |
| Other Operating Activity | 7,232 | 6,089 | 4,188 | 3,043 | 3,143 |
| Operating Cash Flow | $-62,602 | $-41,468 | $-27,416 | $-15,736 | $-52,067 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -532 | -456 | -182 | -25 | -267 |
| Investing Cash Flow | $-532 | $-456 | $-182 | $-25 | $-267 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 47,884 | 47,539 | 47,530 | 47,349 | 101,931 |
| Other Financing Activity | 0 | 0 | 0 | 0 | -960 |
| Financing Cash Flow | $47,884 | $47,539 | $47,530 | $47,349 | $100,971 |
| Beginning Cash Position | 87,304 | 87,304 | 87,304 | 87,304 | 38,667 |
| End Cash Position | 72,054 | 92,919 | 107,236 | 118,892 | 87,304 |
| Net Cash Flow | $-15,250 | $5,615 | $19,932 | $31,588 | $48,637 |
| Free Cash Flow | |||||
| Operating Cash Flow | -62,602 | -41,468 | -27,416 | -15,736 | -52,067 |
| Capital Expenditure | -552 | -456 | -182 | -25 | -267 |
| Free Cash Flow | -63,154 | -41,924 | -27,598 | -15,761 | -52,334 |